Moody Aldrich Partners LLC Makes New $2.16 Million Investment in MoonLake Immunotherapeutics (NASDAQ:MLTX)

Moody Aldrich Partners LLC purchased a new stake in MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) during the first quarter, according to its most recent 13F filing with the SEC. The firm purchased 55,245 shares of the company's stock, valued at approximately $2,158,000. Moody Aldrich Partners LLC owned approximately 0.09% of MoonLake Immunotherapeutics as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. PNC Financial Services Group Inc. raised its stake in shares of MoonLake Immunotherapeutics by 3.9% during the 4th quarter. PNC Financial Services Group Inc. now owns 8,500 shares of the company's stock worth $460,000 after acquiring an additional 320 shares in the last quarter. Teacher Retirement System of Texas grew its holdings in MoonLake Immunotherapeutics by 18.4% in the fourth quarter. Teacher Retirement System of Texas now owns 6,532 shares of the company's stock worth $354,000 after purchasing an additional 1,013 shares during the last quarter. Sei Investments Co. grew its holdings in MoonLake Immunotherapeutics by 5.8% in the fourth quarter. Sei Investments Co. now owns 22,025 shares of the company's stock worth $1,193,000 after purchasing an additional 1,202 shares during the last quarter. KLP Kapitalforvaltning AS acquired a new position in shares of MoonLake Immunotherapeutics during the fourth quarter worth $244,000. Finally, LPL Financial LLC increased its position in shares of MoonLake Immunotherapeutics by 19.5% during the fourth quarter. LPL Financial LLC now owns 8,146 shares of the company's stock worth $441,000 after purchasing an additional 1,332 shares in the last quarter. 93.85% of the stock is currently owned by institutional investors.

MoonLake Immunotherapeutics Price Performance

Shares of MLTX opened at $46.37 on Friday. The company has a debt-to-equity ratio of 0.18, a current ratio of 21.11 and a quick ratio of 21.11. The company's fifty day moving average price is $42.41 and its 200-day moving average price is $42.88. MoonLake Immunotherapeutics has a 1-year low of $31.42 and a 1-year high of $58.26. The firm has a market capitalization of $2.97 billion, a PE ratio of -20.16 and a beta of 1.27.

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) last issued its quarterly earnings results on Monday, May 12th. The company reported ($0.63) EPS for the quarter, topping analysts' consensus estimates of ($0.76) by $0.13. During the same period last year, the firm posted ($0.22) EPS. On average, equities research analysts predict that MoonLake Immunotherapeutics will post -1.79 EPS for the current year.

Analysts Set New Price Targets

A number of analysts have recently weighed in on MLTX shares. Wedbush reissued an "outperform" rating and issued a $80.00 price objective (up previously from $78.00) on shares of MoonLake Immunotherapeutics in a research report on Tuesday, May 13th. Wolfe Research upgraded MoonLake Immunotherapeutics from a "peer perform" rating to an "outperform" rating and set a $61.00 price target for the company in a research note on Monday, May 19th. Needham & Company LLC reissued a "buy" rating and issued a $66.00 price target on shares of MoonLake Immunotherapeutics in a report on Tuesday, May 13th. Finally, Royal Bank Of Canada restated an "outperform" rating and set a $67.00 price target on shares of MoonLake Immunotherapeutics in a research note on Tuesday, June 3rd. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of "Buy" and a consensus target price of $74.50.

MoonLake Immunotherapeutics Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.